Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy
Phase 3UNKNOWNDevelopment Stage
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jul 13, 2020 → Jun 30, 2025
About Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation. The current trial status is unknown. This product is registered under clinical trial identifier NCT04296370. Target conditions include Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation.
What happened to similar drugs?
3 of 20 similar drugs in Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04296370 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation